Home
Indication Area
NRT
Pharma
Partners
Team
Newsroom
CONTACT US
Home
Indication Area
NRT
Pharma
Partners
Team
Newsroom
contact us
Home
Indication Area
NRT
Pharma
Partners
Team
Newsroom
Home
Indication Area
NRT
Pharma
Partners
Team
Newsroom
CONTACT US
Have a Project in Mind? Say Hi!
+1 800 123 456 789
+1 800 123 654 987
Mon - Sun: 10am - 10pm
27 Division St, New York,
NY 10002, USA
grido@mail.com
Home
Archive by Category "PR Neweswire"
PR Neweswire
Category:
PR Neweswire
January 7, 2025
PR Neweswire
BY
admin
Qnovia, Inc. Announces First Patient Dosed in U.S. in Phase 1 study for RespiRx™ Nicotine Inhaler as a prescription smoking cessation therapy
December 10, 2024
PR Neweswire
BY
admin
Qnovia, Inc. Raises $16 Million in Series B Financing to Advance Lead Asset RespiRx™ Nicotine Inhaler as a Prescription Smoking Cessation Therapy
October 21, 2024
PR Neweswire
BY
admin
Qnovia, Inc. CEO Speaks at FDA and NIH Public Meeting to Encourage Innovation of Smoking Cessation Treatment Options
October 1, 2024
PR Neweswire
BY
admin
Qnovia, Inc. announces FDA clearance of IND application for lead asset RespiRx™ Nicotine Inhaler as a prescription smoking cessation therapy
#side-panel.side-panel {width: 500px;}#side-panel.side-panel .side-panel_sidebar {padding: 70px 0px 50px 60px;background-color: #FFFFFF;}
Qnovia